Skip to content
Our Office +972-8-9301-015 |office@biokine.com
Biokine Therapeutics Logo Biokine Therapeutics Logo Biokine Therapeutics Logo
  • Home
  • About Biokine
    • Company Profile
    • Board of Directors
    • Management Team
  • Pipeline
    • Clinical
  • News & Events
  • Partnering
  • Contact
  • Home
  • About Biokine
    • Company Profile
    • Board of Directors
    • Management Team
  • Pipeline
    • Clinical
  • News & Events
  • Partnering
  • Contact

BioLineRx Presents Preclinical Data at ASCO-SITC Showing BL-8040 Prolongs Survival by Mediating Tumor Infiltration of Antigen-Specific T-cells

Home/Clinical Program BL8040/BioLineRx Presents Preclinical Data at ASCO-SITC Showing BL-8040 Prolongs Survival by Mediating Tumor Infiltration of Antigen-Specific T-cells
Previous Next

BioLineRx Presents Preclinical Data at ASCO-SITC Showing BL-8040 Prolongs Survival by Mediating Tumor Infiltration of Antigen-Specific T-cells

developer2021-06-03T05:56:15+00:00
Copyright © 2022 Biokine LTD | All Rights Reserved | Site By: Psik Advertising
FacebookTwitterInstagramPinterest
Page load link
Go to Top